242 related articles for article (PubMed ID: 22054233)
1. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
Dhillon S
Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Dhillon S
Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Frampton JE
Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
5. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Greenspoon J; Herrmann N; Adam DN
CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
8. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
10. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
11. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Reñé R; Ricart J; Hernández B;
Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
[TBL] [Abstract][Full Text] [Related]
12. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
Winblad B; Machado JC
Expert Opin Drug Deliv; 2008 Dec; 5(12):1377-86. PubMed ID: 19040398
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Sadowsky CH; Farlow MR; Meng X; Olin JT
Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
[TBL] [Abstract][Full Text] [Related]
15. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Pregelj P
Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
[TBL] [Abstract][Full Text] [Related]
17. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
Amanatkar HR; Grossberg GT
Expert Rev Neurother; 2014 Oct; 14(10):1119-25. PubMed ID: 25201245
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
19. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
20. Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial.
Schurad B; Koch C; Schug B; Morte A; Vaqué A; De la Torre R; Iniesta M
Curr Alzheimer Res; 2022; 19(7):541-553. PubMed ID: 36017827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
